Organon (OGN) Stock Dips While Market Gains: Key Facts
Organon (OGN) concluded the recent trading session at $18.58, signifying a -1.33% move from its prior day's close.
Why Organon (OGN) Outpaced the Stock Market Today
Organon (OGN) reachead $19.17 at the closing of the latest trading day, reflecting a +0.74% change compared to its last close.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Organon to buy therapy developer Dermavant for up to $1.2 billion
Healthcare company Organon said on Wednesday it has agreed to acquire Dermavant, a Roivant company, for up to $1.2 billion.
Organon (OGN) Outperforms Broader Market: What You Need to Know
Organon (OGN) concluded the recent trading session at $20.47, signifying a +0.89% move from its prior day's close.
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Is Trending Stock Organon & Co. (OGN) a Buy Now?
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Most-Watched Stock Organon & Co. (OGN) Worth Betting on Now?
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon (OGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon (OGN) Surpasses Q2 Earnings Estimates
Organon (OGN) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.31 per share a year ago.
Top 4 stocks that could thrive if Kamala Harris wins the 2024 US election
As the 2024 US presidential election approaches, speculation about Kamala Harris potentially stepping into the Oval Office remains strong. Despite Donald Trump's assertion that Harris would be an easier opponent than Joe Biden, recent developments suggest Harris's presidency is a viable scenario.
